An experimental blood test has detected prostate cancer so accurately that it could supplant PSA levels as a screening mechanism for the disease, according to researchers.

ANAHEIM, Calif.—Declines in prostate cancer deaths are associated with an increase in PSA screening, although the effect is greater in white than in black men, according to researchers at the University of Alabama-Birmingham.

ANAHEIM, Calif.—Moderate to severe lower urinary tract symptoms (LUTS) are present in 42% of men over age 50 who visit their primary-care physician (PCP), according to data presented here at the American Urological Association annual meeting.

TORONTO—Six months of testosterone supplementation in older men with moderately low testosterone levels appears to be relatively safe, with little or no negative effects on the prostate, according to researchers in The Netherlands.

ANAHEIM, Calif.—Prostate cancers found as a result of PSA screening are less likely to exhibit extracapsular extension and positive surgical margins after radical prostatectomy than tumors found in a non-screened population, despite similar PSA levels, data show.

ANAHEIM, Calif.—Statins can significantly reduce PSA levels in healthy men, and the magnitude of this decline is proportional to the extent to which the drugs reduce cholesterol levels, according to researchers.

ANAHEIM, Calif.—Fifteen percent of older men managed with watchful waiting for low-risk prostate tumors detected by PSA screening will die from the malignancy in 10 years, despite a high death rate from competing causes, a study found.

An experimental blood test has detected prostate cancer so accurately that it could supplant PSA levels as a screening mechanism for the disease, according to researchers.

For some men with localized prostate cancer, active surveillance has emerged in recent years as a viable management option. Defined as rigorous monitoring with the option of initiating potentially curative therapy should disease progress, this approach generally has been considered for patients with early, indolent disease (T1c or T2a tumors, a Gleason score of no more than 6, and a PSA level not greater than 10 ng/mL).

PROSTATE BIOPSIES may be unwarranted in men aged 80 years and older and who have a PSA level of 30 ng/mL, according to investigators in the U.K.